TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Actinogen Medical ( (AU:ACW) ) has issued an announcement.
Actinogen Medical announced the results of its Annual General Meeting, where all resolutions, including the approval of increased placement capacity, were carried. The company is advancing its clinical trials for Xanamem, a promising treatment for Alzheimer’s and depression, with significant progress in ongoing trials. The XanaMIA Phase 2b/3 trial for Alzheimer’s is set to be fully enrolled by the end of 2025, with initial results expected in early 2026. Actinogen’s efforts in controlling brain cortisol levels through Xanamem have shown promising safety and efficacy in clinical trials, reinforcing its potential impact on the treatment of neurological diseases.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease, Depression, and potentially other conditions like Fragile X Syndrome. The company aims to address the substantial unmet medical need for improved treatments for cognitive dysfunction and behavioral abnormalities associated with these diseases.
Average Trading Volume: 3,723,869
Technical Sentiment Signal: Buy
Current Market Cap: A$165.3M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.